

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated 9 June 2015 (the “Prospectus”) issued by Pa Shun Pharmaceutical International Holdings Company Limited (the “Company”). This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.*

*This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilising) Rules (Chapter 571W of the Laws of Hong Kong) (the “Stabilising Rules”) and is for information purposes only and does not constitute an offer or an invitation by any person to acquire, purchase or subscribe for securities of the Company.*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of securities in the United States.*



**百信集團**  
PASHUN GROUP

**Pa Shun Pharmaceutical International Holdings Limited**  
**百信藥業國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 574)**

**STABILISING ACTIONS, END OF STABILISATION PERIOD AND  
LAPSE OF THE OVER-ALLOTMENT OPTION**

The Company announces that the stabilisation period in connection with the Global Offering ended on Sunday, 12 July 2015, being the 30<sup>th</sup> day after the last day for the lodging of applications under the Hong Kong Public Offer.

The Company was informed that the stabilising actions undertaken by China Everbright Securities (HK) Limited, the stabilising manager and the Sole Global Coordinator, or any person acting for it, during the stabilisation period involved:

- (i) over-allocations of an aggregate of 37,500,000 Shares in the International Placing, representing 15% of the Offer Shares initially available under the Global Offering;
- (ii) borrowing of an aggregate of 37,500,000 Shares by China Everbright Securities (HK) Limited from Praise Treasure Limited to cover the over-allocations in the International Placing; and
- (iii) purchases of an aggregate of 37,500,000 Shares in the price range of HK\$1.15 to HK\$1.22 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilisation period. The last purchase made by China Everbright Securities (HK) Limited on the market during the course of stabilisation period was on 7 July 2015 at the price of HK\$1.172 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

The Company further announces that the Over-allotment Option had not been exercised by the Sole Global Coordinator on behalf of the International Underwriters during the stabilisation period and lapsed on Sunday, 12 July 2015. Accordingly, no Share was or will be issued under the Over-allotment Option.

## **STABILISING ACTIONS AND END OF STABILISATION PERIOD**

The Company makes this announcement pursuant to section 9(2) of the Securities and Futures (Price Stabilising) Rules (Chapter 571W of the Laws of Hong Kong), that the stabilisation period in connection with the Global Offering ended on 12 July 2015, being the 30<sup>th</sup> day after the last day for the lodging of applications under the Hong Kong Public Offer.

The Company was informed that the stabilising actions undertaken by China Everbright Securities (HK) Limited, the stabilising manager and the Sole Global Coordinator, or any person acting for it, during the stabilisation period involved:

- (i) over-allocations of an aggregate of 37,500,000 Shares in the International Placing, representing 15% of the Offer Shares initially available under the Global Offering;
- (ii) borrowing of an aggregate of 37,500,000 Shares by China Everbright Securities (HK) Limited from Praise Treasure Limited to cover the over-allocations in the International Placing; and

- (iii) purchases of an aggregate of 37,500,000 Shares in the price range of HK\$1.15 to HK\$1.22 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilisation period. The last purchase made by China Everbright Securities (HK) Limited on the market during the course of stabilisation period was on 7 July 2015 at the price of HK\$1.172 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

#### **LAPSE OF THE OVER-ALLOTMENT OPTION**

The Company further announces that the Over-allotment Option had not been exercised by the Sole Global Coordinator on behalf of the International Underwriters during the stabilization period and lapsed on Sunday, 12 July 2015. Accordingly, no Share was or will be issued under the Over-allotment Option.

The Company continues to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules whereby at least 25% of the Company's total issued share capital must at all times be held by the public.

By order of the Board of Directors  
**Pa Shun Pharmaceutical International Holdings Limited**  
**Mr. Chen Yenfei**  
陳燕飛  
*Chairman*

Hong Kong, 12 July 2015

*As at the date of this announcement, the executive Directors are Mr. Chen Yenfei, Mr. Su Si, Mr. Shen Shun, Mr. Zhou Jian; the non-executive Director is Mr. Li Ho Tan and Mr. Masahiro Honna; and the independent non-executive Directors are Mr. Liu Liang Zhong, Mr. Wong Tak Shing and Mr. Min Feng.*